1. NEK1 mutations and the risk of amyotrophic lateral sclerosis (ALS): a meta-analysis
- Author
-
Baolong Cui, Luqing Yao, Xiaoyan He, Fang Zhao, and Chang Zhou
- Subjects
medicine.medical_specialty ,Mutation rate ,Neurology ,Subgroup analysis ,Dermatology ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Asian People ,Internal medicine ,medicine ,Humans ,Missense mutation ,030212 general & internal medicine ,Amyotrophic lateral sclerosis ,Loss function ,business.industry ,Amyotrophic Lateral Sclerosis ,General Medicine ,medicine.disease ,Psychiatry and Mental health ,NIMA-Related Kinase 1 ,Case-Control Studies ,Meta-analysis ,Mutation ,Neurology (clinical) ,Neurosurgery ,business ,030217 neurology & neurosurgery - Abstract
Recently, NEK1 (NIMA-related kinase 1) mutations were identified as a cause of amyotrophic lateral sclerosis (ALS), but the relationship between them remains unclear owing to the small sample size and low mutation rate. We made a meta-analysis to make clear the relationship. Eight case-control studies involving 8603 cases and 18,695 controls were enrolled. Results demonstrated that the frequency of NEK1 mutations was 3.1% (95% CI 2.5–3.8%) in ALS patients, including the frequencies of loss of function (LoF) and missense mutations, which were 0.9% (95% CI 0.6–1.1%) and 2.3% (95% CI 1.7–2.8%) in ALS patients, respectively. NEK1 mutations (OR 2.14; 95% CI 1.81–2.52; p
- Published
- 2021
- Full Text
- View/download PDF